Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Neuroblastoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Yizhuo Zhang, Guangzhou, Guangdong, China
Contact: Study coordinator (Yizhuo Zhang) · zhangyzh@sysucc.org.cn · 87342460

Study leads

Yizhuo Zhang
Principal Investigator
Sun Yat-Sen University Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

High-risk Neuroblastoma · Neuroblastoma · Childhood Neuroblastoma

Abroad (travel likely)RecruitingPHASE2

New York, United States

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Neuroblastoma

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · San Francisco, United States

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Neuroblastoma · Ewing Sarcoma · Osteosarcoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Phoenix, United States

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Neuroblastoma

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China